Apalutamide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Apalutamide. Educational only — not medical advice.
Labeled uses
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC)
Source: FDA labeling via NIH DailyMed (set d1cda4f7…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.